Evidence map›Paper›PMID 31827779›Full record

ArticleAntimicrobial resistance and infection control2019

Clinical outcomes of hospitalised patients with catheter-associated urinary tract infection in countries with a high rate of multidrug-resistance: the COMBACTE-MAGNET RESCUING study.

Aina Gomila, Jordi Carratalà, Noa Eliakim-Raz, Evelyn Shaw, Cristian Tebé, Martin Wolkewitz, Irith Wiegand, Sally Grier, Christiane Vank, Nienke Cuperus and 7 more

Open access · goldAbstract readMulticenter Study
In one paragraph

Article in Antimicrobial resistance and infection control, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 2 pooled it
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 2 syntheses or guidelines pooled it, 52 citations in OpenAlex.

  1. Assessing the economic burden of complicated urinary tract infection: A systematic literature review.The European journal of health economics : HEPAC : health economics in prevention and care · 2026
    Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Observational
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 9 institutions in 5 countries.

Aina Gomila1Department of Infectious Diseases, Hospital Universitari de Bellvitge-Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Institut Català de la Salut (ICS-HUB), Barcelona, Spain.ORCID 0000-0001-6979-9269
Jordi Carratalà1Department of Infectious Diseases, Hospital Universitari de Bellvitge-Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Institut Català de la Salut (ICS-HUB), Barcelona, Spain.
Noa Eliakim-Raz5Department of Medicine E, Beilinson Hospital, Rabin Medical Center, Petah-Tiqva; and Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
Evelyn Shaw1Department of Infectious Diseases, Hospital Universitari de Bellvitge-Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Institut Català de la Salut (ICS-HUB), Barcelona, Spain.
Cristian Tebé6Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) and Department of Basic Sciences, Universitat Rovira i Virgili, Tarragona, Spain.
Martin Wolkewitz7Institute of Medical Biometry and Statistics, University of Freiburg, Freiburg, Germany.
Irith WiegandAiCuris Anti-infective Cures GmbH, Wuppertal, Germany.
Sally Grier9Department of Medical Microbiology, Southmead Hospital, North Bristol NHS Trust, Bristol, UK.
Christiane VankAiCuris Anti-infective Cures GmbH, Wuppertal, Germany.
Nienke Cuperus10Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, Netherlands.
Leonard Van den Heuvel10Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, Netherlands.
Cuong VuongAiCuris Anti-infective Cures GmbH, Wuppertal, Germany.
Alasdair MacGowan9Department of Medical Microbiology, Southmead Hospital, North Bristol NHS Trust, Bristol, UK.
Leonard Leibovici5Department of Medicine E, Beilinson Hospital, Rabin Medical Center, Petah-Tiqva; and Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
Ibironke AddyAiCuris Anti-infective Cures GmbH, Wuppertal, Germany.
Miquel Pujol1Department of Infectious Diseases, Hospital Universitari de Bellvitge-Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Institut Català de la Salut (ICS-HUB), Barcelona, Spain.
RESCUING Study Group and Study Sites
North Bristol NHS Trust · GBUniversity Medical Center Utrecht · NLBellvitge University Hospital · ESInstitut d'Investigació Biomédica de Bellvitge · ESRabin Medical Center · ILInstituto de Salud Carlos III · ESTel Aviv University · ILUniversity Medical Center Freiburg · DEUniversity of Freiburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Although catheter-associated urinary tract infection (CA-UTI) is a major healthcare-related problem worldwide, there is a scarcity of current data from countries with high antimicrobial resistance rates. We aimed to determine the clinical outcomes of patients with CA-UTI compared to those of patients with other sources of complicated urinary tract infection (cUTI), and to assess the impact of antimicrobial resistance. We also aimed to identify the factors influencing 30-day mortality among patients with CA-UTI. Methods: This was a multicentre, multinational retrospective cohort study including hospitalised adults with cUTI between January 2013 and December 2014 in twenty hospitals from eight countries from southern Europe, Turkey and Israel. The primary endpoint was 30-day mortality. The secondary endpoints were length of hospital stay, symptom improvement after 7 days' treatment, symptom recurrence at 30 days and readmission 60 days after hospital discharge. Results: Of the 807 cUTI episodes, 341 (42.2%) were CA-UTIs. The time from catheter insertion to cUTI diagnosis was less than 2 weeks in 44.6% of cases. Overall, 74.5% of cases had hospital or healthcare-acquired CA-UTI. Compared to patients with other cUTI aetiologies, those with CA-UTI had the following characteristics: they were more frequently males, older, admitted for a reason other than cUTI and admitted from a long-term care facility; had higher Charlson's comorbidity index; and more frequently had polymicrobial infections and multidrug-resistant Gram-negative bacteria (MDR-GNB). Patients with CA-UTI also had significantly higher 30-day mortality rates (15.2% vs 6%) and longer hospital stay (median 14 [interquartile range -IQR- 7-27] days vs 8 [IQR 5-14] days) than patients with cUTI of other sources. After adjusting for confounders, CA-UTI was not independently associated with an increased risk of mortality (odds ratio, 1.40; 95% confidence interval, 0.77-2.54), and neither was the presence of MDR-GNB. Conclusions: CA-UTI was the most frequent source of cUTI, affecting mainly frail patients. The mortality of patients with CA-UTI was high, though this was not directly related to the infection.

Indexed as

Drug Resistance, Multiple, BacterialHospitalizationAgedAged, 80 and overAnti-Bacterial AgentsCatheter-Related InfectionsCross InfectionEuropeFemaleFrailtyGram-Negative Bacterial InfectionsHospital MortalityHumansInternationalityIsraelLength of StayAnti-Bacterial AgentsAntimicrobial resistanceCatheter-associated urinary tract infectionGram-negative infections

Identifiers

PMID31827779
PMCPMC6892205
OpenAlexW2992134533

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.